Variable | Non-relapsed (n = 20) | Relapsed (n = 12) | Mean Difference | Std. Error Difference | p-value |
---|---|---|---|---|---|
Age of onset, year | 33.35 | 33.16 | −0.183 | 4.740 | 0.969 |
Mean BMI | 23.89 | 24.63 | 0.741 | 1.415 | 0.604 |
Disease duration, months | 80.40 | 94.17 | 13.77 | 25.81 | 0.589 |
Duration of AZA therapy, months | 22.10 | 20.50 | −1.6 | 2.278 | 0.488 |
Mean CSF protein, mg/dl | 39.82 | 41.43 | 1.613 | 13.275 | 0.904 |
Mean Concentration of CSF IgG, mg/ml | 0.040 | 0.032 | −0.008 | 0.014 | 0.577 |
CSF IgG index (n%) | 0.546 | 0.494 | −0.519 | 0.039 | 0.199 |
Serum anti-AQP4 antibodies (n%) | 10 (50%) | 4 (33.3%) | / | / | 0.471 |
Pre-therapy EDSS score | 5.17 | 5.29 | / | / | 0.687 |
Post- therapy EDSS score | 2.43 | 2.83 | / | / | 0.893 |
Normalized concentration of 6-TGNs | 1.12 | 0.70 | −0.418 | 0.09 | <0.0001* |
Normalized concentration of 6-MMPNs | 10.60 | 3.62 | −6.983 | 2.32 | 0.006* |